Clinical trials: Migraine Headache, With or Without Aura
Migraine
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)
Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea, vomiting, and sensitivity to light and sound.
- Trial name
- UBRO PEDS OLE (NCT05127954)
- Testing
- Ubrogepant
- Where
- 113 sites in United States, Puerto Rico
- Volunteers
- 1,200 people
- Sponsor
- AbbVie
Migraine
Safety and Efficacy Study of MK0974 in the Acute Migraine (0974-016)
The purpose of this study is to investigate the efficacy and safety of MK0974 compared to a placebo for acute migraine.
- Trial name
- NCT00432237
- Testing
- MK0974 50 mg, MK0974 150 mg, MK0974 300 mg
- Volunteers
- 1,703 people
- Sponsor
- Merck Sharp & Dohme LLC
Migraine, Migraine Headache
The Impact of Acupuncture on Biomarkers of Brain Injury and Inflammatory Response in Migraine
Migraine is more than just a headache-it can involve changes in the brain and inflammation. Recent research suggests that acupuncture may help by calming pain signals and reducing inflammation in the body.
- Conditions
- Migraine, Migraine Headache, Migraine Headache, With or Without Aura, Migraine in Adults
- Trial name
- ACUPMIGRAINE (NCT07292506)
- Testing
- Standard acupuncture, Electroacupuncture, Laser Acupuncture
- Where
- Slovenia
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- University Medical Centre Ljubljana
Migraine, With or Without Aura
Safety and Efficacy Study in Adult Subjects With Acute Migraines
The purpose of this study is to compare the efficacy of BHV-3000 (rimegepant) versus placebo in subjects with Acute Migraines
- Trial name
- NCT03235479
- Testing
- Rimegepant
- Where
- 50 sites in United States
- Volunteers
- 1,485 people
- Sponsor
- Pfizer
Migraine, Migraine Disease
Assessment of Oral Caffeine Intake in Changing the Severity of Acute Migraine Attack Using VAS Score Among Patients Attending Headache and Neurology Outpatients Clinic of Ainshams University Hospitals
Caffeine extracted from green tea to abort acute attack of Migraine
- Conditions
- Migraine, Migraine Disease, Migraine Headache, Migraine Headache, With or Without Aura
- Trial name
- NCT07022496
- Testing
- Caffeine (200 mg), triptans, NSAID (Nonsteroidal anti-inflammatory drugs)
- Where
- Egypt
- Volunteers
- 120 people
- Sponsor
- Ain Shams University
Migraine Disorders
A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2)
This is a randomized, double-blind, placebo-controlled, crossover, two-attack, out-patient, early-intervention evaluation of subjects who have migraine with or without aura and who discontinued use of short acting triptan(s)…
- Trial name
- NCT00382993
- Testing
- Combination Product (sumatriptan succinate/naproxen sodium)
- Where
- 28 sites in United States
- Volunteers
- 169 people
- Sponsor
- GlaxoSmithKline
Migraine
Two Dose Levels of DFN-15 vs. Placebo in Patients With Migraine Headaches
Crossover study of DFN-15 dose A versus DFN-15 dose B versus Placebo in the treatment of migraine headaches.
- Trial name
- NCT02472418
- Testing
- DFN-15 Dose A (treatment A), DFN-15 Dose B (treatment B)
- Where
- 6 sites in United States
- Volunteers
- 63 people
- Sponsor
- Dr. Reddy's Laboratories Limited
Migraine With or Without Aura
Eletriptan for the Treatment of Migraine in Patients With Previous Poor Response or Tolerance to Oral Sumatriptan
To determine the tolerability and efficacy of eletriptan in patients who had discontinued oral sumatriptan due to lack of efficacy or intolerable adverse events (AEs) during previous clinical treatment (not a controlled trial).
- Trial name
- NCT01989936
- Testing
- Eletriptan 40 mg, Eletriptan 80 mg
- Where
- 43 sites in Denmark, Finland and 3 more
- Volunteers
- 446 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Migraine, With or Without Aura
Long-term Safety of BR005-036C Tablets in the Acute Treatment of Migraine in Adults
The purpose of this study is to evaluate the long-term safety of BR005-036C tablets in the acute treatment of migraines
- Trial name
- NCT07835152
- Testing
- BR005-036C
- Where
- 81 sites in China
- Volunteers
- 1,000 people
- Sponsor
- Brise Pharmaceuticals Co., Ltd.
Migraine
Pharmacokinetics & Safety of Cambia® in Migraine With or Without Aura in 12-17 Year Olds
Study Objectives: 1. The primary objective is to characterize the pharmacokinetics of a single oral administration of 50 mg Cambia in pediatric subjects, ages 12-17 years with a diagnosis of episodic migraine with or without…
- Trial name
- NCT02287376
- Testing
- Diclofenac Potassium for Oral Solution
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Depomed
Pediatric Migraine
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in children and adolescents.
- Trial name
- NCT04649242
- Testing
- Rimegepant/BHV3000
- Where
- 246 sites in United States, Canada and 7 more
- Volunteers
- 2,100 people
- Sponsor
- Pfizer
Migraine Headache
Efficacy, Tolerability, and Safety of DFN-15
Efficacy, Tolerability, and Safety of DFN-15 in episodic migraine with or without aura, being conducted at multiple centers in the United States
- Trial name
- NCT03009019
- Testing
- DFN-15 Active
- Where
- 43 sites in United States
- Volunteers
- 631 people
- Sponsor
- BioDelivery Sciences International
Migraine Disorders, Migraine With Aura
Continue or Stop Applying Wet Cupping (Al-Hijamah) in Migraine
This study evaluates the short and long-term effects of application of Wet Cupping Therapy (WCT) in the treatment of migraine headaches in adults.Half of the participants will continue WCT application and the other half will not.
- Conditions
- Migraine Disorders, Migraine With Aura, Migraine Without Aura
- Trial name
- NCT03479060
- Testing
- Wet Cupping
- Where
- Turkey (Türkiye)
- Volunteers
- 109 people
- Sponsor
- Karabuk University
Migraine Headache, With or Without Aura
Staccato Prochlorperazine in Migraine (in Clinic)
Development of Staccato Prochlorperazine for the treatment of migraine headache.
- Trial name
- NCT00610428
- Testing
- Staccato Prochlorperazine 5 mg, Staccato Prochlorperazine 10 mg
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Alexza Pharmaceuticals, Inc.
Migraine With or Without Aura
Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine
This is a prospective randomized, double-blind, placebo-controlled study in participants with disabling migraine (Migraine Disability Assessment (MIDAS) score ≥ 11).
- Trial name
- SPARTAN (NCT02605174)
- Testing
- Lasmiditan 50 mg, Lasmiditan 100 mg, Lasmiditan 200 mg
- Where
- 95 sites in United States
- Volunteers
- 3,005 people
- Sponsor
- Eli Lilly and Company
Migraine With or Without Aura
Efficacy, Safety, and Tolerability of Oral Eletriptan for Treatment of Acute Migraine
To confirm the efficacy of three dose levels of oral eletriptan relative to placebo in relieving symptoms of acute migraine and to further explore the dose response relationship of eletriptan.
- Trial name
- NCT01978496
- Testing
- Eletriptan 20 mg, Eletriptan 40 mg, Eletriptan 80 mg
- Volunteers
- 1,334 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Migraine, Without Aura
TREXIMET (Formerly Known as TREXIMA) for the Acute Treatment of Probable Migraine (ICHD-II 1.6.1)
This study was designed to determine the efficacy and tolerability of TREXIMET (formerly known as TREXIMA) compared to placebo for the acute treatment of probable migraine, a sub-type of migraine.
- Trial name
- NCT00387881
- Testing
- sumatriptan succinate / naproxen sodium
- Where
- 70 sites in United States
- Volunteers
- 679 people
- Sponsor
- GlaxoSmithKline
Migraine, With or Without Aura
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (25 and 50 mg) compared to placebo for the acute treatment of a single migraine attack.
- Trial name
- ACHIEVE II (NCT02867709)
- Testing
- Ubrogepant
- Where
- 109 sites in United States
- Volunteers
- 1,686 people
- Sponsor
- Allergan
Cluster Headache - Episodic and Chronic, Migraine Headache
Yogabased Movements for Primary Headaches (Migraine and/or Cluster Headache) - YOURHEAD - a Pilot Study
Migraine and/or Cluster Headache: Study Overview Background: Migraine and cluster headache are two primary headache disorders that significantly impact quality of life and functionality in those affected.
- Conditions
- Cluster Headache - Episodic and Chronic, Migraine Headache, Migraine Headache, With or Without Aura, Migraine in Adults
- Trial name
- NCT07292090
- Testing
- Intervention yogabased movements
- Where
- Sweden
- Volunteers
- 20 people
- Sponsor
- Karolinska Institutet
Acute Treatment of Migraine
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of migraine in children and adolescents (≥ 6 to < 18 years of age).
- Trial name
- NCT04743141
- Testing
- Rimegepant (PF-07899801)
- Where
- 124 sites in United States, Poland and 1 more
- Volunteers
- 600 people
- Sponsor
- Pfizer